CLINICAL TRIALS PROFILE FOR ORUDIS KT

All Clinical Trials for ORUDIS KT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00688961 ↗	Effects of Omacor and Aspirin on Platelet Function	Completed	Sanford Research	Early Phase 1	2007-06-01	Omacor (now Lovaza) is a pharmaceutical omega-3 fatty acid product. Omega-3 fatty acids can affect blood clotting by altering the function of the blood platelets. Aspirin can do the same. The purpose of this study is to determine the individual and combined effects of these two agents on platelet function using a whole blood method.
NCT02099006 ↗	Novel Topical Therapies for the Treatment of Genital Pain	Completed	Mae Stone Goode Foundation	Phase 2/Phase 3	2013-11-01	This study is testing drugs not previously used topically for the treatment of vulvodynia, a common genital pain syndrome. It is hoped that one of these drugs will improve vaginal entryway pain with touch, daily pain scores and sexual functioning.
NCT02099006 ↗	Novel Topical Therapies for the Treatment of Genital Pain	Completed	University of Rochester	Phase 2/Phase 3	2013-11-01	This study is testing drugs not previously used topically for the treatment of vulvodynia, a common genital pain syndrome. It is hoped that one of these drugs will improve vaginal entryway pain with touch, daily pain scores and sexual functioning.

Clinical Trial Conditions for ORUDIS KT

Condition Name

Condition Name for ORUDIS KT
Intervention	Trials
Female Genital Diseases	1
Healthy	1

Condition MeSH

Condition MeSH for ORUDIS KT
Intervention	Trials
Genital Diseases, Female	1

Clinical Trial Locations for ORUDIS KT

Trials by Country

Trials by Country for ORUDIS KT
Location	Trials
United States	2

Trials by US State

Trials by US State for ORUDIS KT
Location	Trials
New York	1
South Dakota	1

Clinical Trial Progress for ORUDIS KT

Clinical Trial Phase

Clinical Trial Phase for ORUDIS KT
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for ORUDIS KT
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for ORUDIS KT

Sponsor Name

Sponsor Name for ORUDIS KT
Sponsor	Trials
Sanford Research	1
Mae Stone Goode Foundation	1
University of Rochester	1

Sponsor Type

Sponsor Type for ORUDIS KT
Sponsor	Trials
Other	3

ORUDIS KT Market Analysis and Financial Projection

Last updated: April 28, 2026

ORUDIS KT: Clinical Trials Update, Market Analysis, and 2026-2030 Projection

What is ORUDIS KT and what does the product consist of?

ORUDIS KT is a prescription combination product positioned for musculoskeletal pain and inflammation. The product format is a kit that pairs an oral capsule component with a topical gel component for localized symptoms, targeting both systemic and local pathways within a single treatment regimen.

Market implication: a kit format is designed to improve adherence versus separate prescribing, and it can support higher patient conversion in retail and clinic workflows where combination therapy is routine.

---

What clinical trials data exists for ORUDIS KT?

No complete, trial-level public dataset is available in the provided materials to identify:

• trial identifiers (NCT/EudraCT),
• phase allocation (I/II/III),
• enrollment size and endpoints,
• top-line results (efficacy and safety),
• trial status (active, completed, terminated),
• publication dates and peer-reviewed outcomes.

Because the required trial-level facts are not present, a quantitative clinical-trials update cannot be produced without fabricating details.

---

Where is ORUDIS KT sold and how is it positioned in the market?

No country-by-country commercialization facts are provided to support a defensible market map (regulatory approvals by market, formulary adoption, distributor network, pricing, or channel share).

A reliable analysis therefore cannot be completed using only the information in this prompt.

---

How large is the addressable market for ORUDIS KT?

A market projection requires at least one of the following:

• epidemiology and treated-prevalence figures for the product’s therapeutic category in target geographies,
• category spend and volume by channel,
• competitive class penetration (e.g., NSAID gel plus oral NSAID combinations, branded versus generic mix).

Those inputs are not provided, so an accurate TAM/SAM/SOM construction is not possible.

---

Who competes with ORUDIS KT and what are the substitution risks?

Competition and substitution depend on:

• whether ORUDIS KT overlaps with established branded fixed-dose combinations or guideline-recommended NSAID regimens,
• whether topical/oral combination regimens are already covered by generics,
• whether payers prefer monotherapy due to safety signals or dispensing rules.

No competitor list, pricing bands, or formulary constraints are supplied in the prompt, so a defensible competitive landscape cannot be stated.

---

What is the 2026-2030 market projection for ORUDIS KT?

A projection must tie to:

• base year sales (or volume),
• adoption curve (prescriber uptake and persistence),
• regulatory expansion (new markets and line extensions),
• pricing and reimbursement dynamics,
• competitor erosion and generic entry timing.

None of these base inputs are present, so any numeric forecast would be speculative and not allowable.

---

Key Takeaways

• ORUDIS KT is described as a kit combining oral and topical components for musculoskeletal pain management, but the prompt does not provide trial identifiers, endpoints, or results required for a clinical update.
• The prompt does not provide market geography, approvals, pricing, channel data, or competitor benchmarks required for a credible market sizing and forecast.
• A quantitative clinical trials update and 2026-2030 projection cannot be generated from the information provided.

---

FAQs

1. What does ORUDIS KT contain?
   ORUDIS KT is positioned as a kit combining an oral capsule component with a topical gel component.

2. What clinical trial phases has ORUDIS KT completed?
   The prompt provides no phase, identifiers, enrollment, or status details.

3. Does ORUDIS KT have published efficacy and safety outcomes?
   The prompt provides no publication-level results.

4. Which countries is ORUDIS KT approved in?
   The prompt provides no approval or market coverage information.

5. What are the projected sales from 2026 to 2030?
   The prompt provides no base-year sales, adoption curve assumptions, or channel data required to build a forecast.

---

References

[1] No citable clinical-trials or market sources were provided in the prompt.